全文获取类型
收费全文 | 3643篇 |
免费 | 305篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 109篇 |
妇产科学 | 108篇 |
基础医学 | 726篇 |
口腔科学 | 49篇 |
临床医学 | 387篇 |
内科学 | 957篇 |
皮肤病学 | 48篇 |
神经病学 | 319篇 |
特种医学 | 316篇 |
外国民族医学 | 9篇 |
外科学 | 350篇 |
综合类 | 62篇 |
预防医学 | 156篇 |
眼科学 | 28篇 |
药学 | 151篇 |
中国医学 | 6篇 |
肿瘤学 | 167篇 |
出版年
2023年 | 21篇 |
2022年 | 14篇 |
2021年 | 33篇 |
2020年 | 22篇 |
2019年 | 45篇 |
2018年 | 76篇 |
2017年 | 53篇 |
2016年 | 57篇 |
2015年 | 60篇 |
2014年 | 90篇 |
2013年 | 109篇 |
2012年 | 193篇 |
2011年 | 172篇 |
2010年 | 123篇 |
2009年 | 139篇 |
2008年 | 158篇 |
2007年 | 127篇 |
2006年 | 149篇 |
2005年 | 150篇 |
2004年 | 131篇 |
2003年 | 134篇 |
2002年 | 135篇 |
2001年 | 130篇 |
2000年 | 109篇 |
1999年 | 105篇 |
1998年 | 84篇 |
1997年 | 79篇 |
1996年 | 91篇 |
1995年 | 68篇 |
1994年 | 66篇 |
1993年 | 74篇 |
1992年 | 76篇 |
1991年 | 70篇 |
1990年 | 61篇 |
1989年 | 91篇 |
1988年 | 80篇 |
1987年 | 71篇 |
1986年 | 73篇 |
1985年 | 58篇 |
1984年 | 41篇 |
1983年 | 33篇 |
1982年 | 35篇 |
1981年 | 28篇 |
1980年 | 25篇 |
1979年 | 21篇 |
1978年 | 24篇 |
1977年 | 25篇 |
1976年 | 29篇 |
1975年 | 21篇 |
1971年 | 16篇 |
排序方式: 共有3960条查询结果,搜索用时 984 毫秒
1.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
2.
3.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
4.
Ectopic prolactin secretion from a gonadoblastoma 总被引:1,自引:0,他引:1
A 6.5-year-old girl developed isosexual, pseudoprecocious puberty secondary to a gonadoblastoma. The tumor was found to produce and secrete both immunoassayable and bioassayable prolactin based on immunohistochemical techniques and the presence of a prolactin gradient between the tumor vein and peripheral vein. The source of the prolactin was a Sertoli-like cell. Neither growth hormone nor growth hormone-releasing hormone was detected within the tumor. This case confirms the ectopic production of prolactin by neoplastic tissue. 相似文献
5.
Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. 总被引:2,自引:0,他引:2
Onder Onguru Bernd W Scheithauer Kalman Kovacs Sergio Vidal Long Jin Shuya Zhang Katharina H Ruebel Ricardo V Lloyd 《Modern pathology》2004,17(7):772-780
Epidermal growth factor receptor plays an important role in the pathogenesis of many malignancies. Various growth factors, including epidermal growth factor receptor, have been shown to influence pituitary tumor growth and differentiation. To analyze the role of epidermal growth factor receptor in pituitary tumor development, we examined normal pituitaries (n=8), pituitary adenomas (n=158), and pituitary carcinomas (n=7) for expression of epidermal growth factor receptor protein and messenger RNA using tissue microarrays and RT-PCR. We also examined (a) the expression of phospho-epidermal growth factor receptor, the activated form of epidermal growth factor receptor, in pituitary tumors and normal pituitaries by immunohistochemistry and (b) the effects on epidermal growth factor receptor expression of treating pituitary cells (HP75 cell line) with epidermal growth factor. Epidermal growth factor receptor and the phosphorylated variant expression were present in normal pituitary cells. Epidermal growth factor receptor messenger RNA was also detected in normal pituitaries, pituitary adenomas, and carcinomas by in situ hybridization and RT-PCR. Most pituitary adenomas showed expression of epidermal growth factor receptor and the phosphorylated variant. Nonfunctional adenomas showed higher levels of expression of epidermal growth factor receptor (76 vs 34%) and of phospho-epidermal growth factor receptor (26 vs 8%) as compared to functional adenomas. Five of seven pituitary carcinomas showed strong expression of both epidermal growth factor receptor and phospho-epidermal growth factor receptor. When a human pituitary cell line (HP75) was cultured in the presence of epidermal growth factor receptor, there was an increase in the levels of both epidermal growth factor receptor and phospho-epidermal growth factor receptor after 5 h of treatment, thus confirming that epidermal growth factor receptor signaling was active in pituitary tumors. These results indicate that activated epidermal growth factor receptor is expressed in pituitary adenomas and carcinomas. Higher levels in pituitary carcinomas suggest a role in pituitary tumor progression. 相似文献
6.
7.
8.
9.
10.